IBRX ▼ -0.2% - ImmunityBio, Inc.
$IBRX FDA WINS FIRST-EVER APPROVAL FOR ANKTIVA IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY BLADDER CANCER social media
14-OCT-2026 11:18 AM ET
Share this post
More filings for $IBRX
IBRX ▲ +0.9% - ImmunityBio, Inc.Oct 21, 2026IBRX ▼ -6.3% - ImmunityBio, Inc.Oct 16, 2026IBRX ▼ -5.8% - ImmunityBio, Inc.Oct 16, 2026IBRX ▲ +2.1% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +2.1% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +1.0% - ImmunityBio, Inc.Oct 14, 2026
View full $IBRX filing history →💬 Comments
Loading comments…
Leave a comment